{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T06:56:20Z","timestamp":1770965780640,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"9816","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/s0140-6736(11)61713-3","type":"journal-article","created":{"date-parts":[[2012,1,18]],"date-time":"2012-01-18T17:21:48Z","timestamp":1326907308000},"page":"617-624","source":"Crossref","is-referenced-by-count":215,"title":["Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study"],"prefix":"10.1016","volume":"379","clinical-trial-number":[{"clinical-trial-number":"nct00661713","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Mar\u00eda Elena","family":"Santolaya","sequence":"first","affiliation":[]},{"given":"Miguel L","family":"O'Ryan","sequence":"additional","affiliation":[]},{"given":"Mar\u00eda Teresa","family":"Valenzuela","sequence":"additional","affiliation":[]},{"given":"Valeria","family":"Prado","sequence":"additional","affiliation":[]},{"given":"Rodrigo","family":"Vergara","sequence":"additional","affiliation":[]},{"given":"Alma","family":"Mu\u00f1oz","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[]},{"given":"Gabriela","family":"Gra\u00f1a","sequence":"additional","affiliation":[]},{"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Ralf","family":"Clemens","sequence":"additional","affiliation":[]},{"given":"Peter M","family":"Dull","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/S0140-6736(11)61713-3_bib1","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(11)61713-3_bib2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(11)61713-3_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","article-title":"Conquering the meningococcus","volume":"31","author":"Stephens","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/S0140-6736(11)61713-3_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1086\/599117","article-title":"Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents","volume":"49","author":"Jackson","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib5","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1097\/INF.0b013e3182054ab9","article-title":"Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age","volume":"30","author":"Baxter","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/S0140-6736(11)61713-3_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib9","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1093\/infdis\/126.5.514","article-title":"Immunologic response of man to group B meninogococcal polysaccharide vaccines","volume":"126","author":"Wyle","year":"1972","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib10","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(11)61713-3_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/0165-5728(90)90146-E","article-title":"Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis","volume":"29","author":"Nedelec","year":"1990","journal-title":"J Neuroimmunol"},{"key":"10.1016\/S0140-6736(11)61713-3_bib12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines\u2014an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"suppl 2","key":"10.1016\/S0140-6736(11)61713-3_bib13","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1086\/648966","article-title":"Review of meningococcal group B vaccines","volume":"50","author":"Granoff","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib14","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against ssrogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"10.1016\/S0140-6736(11)61713-3_bib15","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"PNAS"},{"key":"10.1016\/S0140-6736(11)61713-3_bib16","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1073\/pnas.0915162107","article-title":"Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans","volume":"107","author":"Serruto","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/S0140-6736(11)61713-3_bib17","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/S0140-6736(11)61713-3_bib18","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1086\/656741","article-title":"Multicentre, open-label, randomised phase II controlled study of an investigational recombinant serogroup B vaccine with and without outer membrane vesicles, administered in infancy","volume":"51","author":"Findlow","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/S0140-6736(11)61713-3_bib20","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1016\/j.vaccine.2010.05.014","article-title":"Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus","volume":"28","author":"Giuliani","year":"2010","journal-title":"Vaccine"},{"issue":"suppl 2","key":"10.1016\/S0140-6736(11)61713-3_bib21","doi-asserted-by":"crossref","first-page":"B112","DOI":"10.1016\/j.vaccine.2009.04.065","article-title":"Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(11)61713-3_bib22","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"PNAS"},{"key":"10.1016\/S0140-6736(11)61713-3_bib23","unstructured":"Donnelly J, Medini D, Giuliani M, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. 11th EMGM conference, Ljubljana, Slovenia; May 18\u201320, 2011. Abstract O 08."},{"key":"10.1016\/S0140-6736(11)61713-3_bib24","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1086\/597806","article-title":"Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa","volume":"199","author":"Beernick","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib25","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1086\/511646","article-title":"Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger","volume":"44","author":"Boisier","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/S0140-6736(11)61713-3_bib26","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1016\/j.vaccine.2010.06.083","article-title":"Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease","volume":"28","author":"Jiang","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/S0140-6736(11)61713-3_bib27","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4161\/hv.3.5.4458","article-title":"Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004\u20132006","volume":"3","author":"McNicholas","year":"2007","journal-title":"Hum Vacc"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673611617133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0140673611617133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T19:09:34Z","timestamp":1686683374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0140673611617133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":25,"journal-issue":{"issue":"9816","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0140673611617133"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(11)61713-3","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}